Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
AT132 has prompted more safety concerns, this time at a lower dose than before.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
A 21% reduction in the risk of cardiovascular death or hospitalisation paves the way for Jardiance's approval in heart failure with preserved ejection fraction.